FDA批准、临床试验证据、疗效、流行病学与价格:非孤儿药与超罕见、罕见及常见孤儿药肿瘤适应症的横断面分析
该横断面分析纳入2000至2022年FDA批准的170种药物、455个肿瘤适应症,比较非孤儿药与超罕见、罕见、常见孤儿药适应症在监管批准、试验设计、流行病学和价格上的差异。超罕见孤儿药适应症更多为首创机制、单药、血液肿瘤、小样本单臂1/2期试验,无进展生存获益更大但总生存无显著差异,月价格更高。作者认为孤儿药法案激励了超罕见病和常见病亚组药物开发,但批准基于小型非稳健试验可能高估疗效。
要点
- 超罕见孤儿药适应症更多为首创机制(76%)、单药(88%)、血液肿瘤(76%),中位试验样本量85例。
- 孤儿药适应症较非孤儿药适应症显示更大无进展生存获益(HR 0.53/0.51/0.49 vs 0.64),总生存获益无显著差异(P=0.06)。
- 超罕见孤儿药适应症月价格最高($70 128),2005至2023年孤儿药价格平均上涨94%。
核心结论
- 1983年孤儿药法案激励了不仅罕见病、还包括超罕见病和常见病亚组的药物开发,这些孤儿药适应症填补了显著未满足需求,但其批准基于小型非稳健试验,可能高估疗效结局。
- 作者认为,设立独立的超孤儿药认定并给予更大财务激励,可鼓励和加速超罕见病药物开发。
研究设计与样本
- 横断面分析,数据来自Drugs@FDA、FDA标签、全球疾病负担研究以及Medicare和Medicaid,纳入2000至2022年FDA批准的170种药物、455个肿瘤适应症。
- 共识别161个非孤儿药肿瘤适应症和294个孤儿药肿瘤适应症,其中25个获批用于超罕见病(美国患者<6600例)、205个用于罕见病(6600-200 000例)、64个用于常见病(>200 000例)。
- 对总生存和无进展生存的风险比进行了Meta分析。
主要发现
- 超罕见孤儿药适应症较罕见、常见孤儿药适应症和非孤儿药适应症更多为首创机制(76% v 48% v 38% v 42%;P<0.001)、单药(88% v 69% v 72% v 55%;P=0.001)、血液肿瘤(76% v 66% v 0% v 0%;P<0.001),试验样本量更小(中位85 v 199 v 286 v 521例;P<0.001),更多为单臂(84% v 44% v 28% v 21%;P<0.001)1/2期设计(88% v 45% v 45% v 27%;P<0.001)。
- 常见孤儿药适应症较罕见和超罕见孤儿药适应症更多为生物标志物导向(69% v 26% v 12%;P<0.001)、一线治疗(77% v 39% v 20%;P<0.001)、小分子药物(80% v 62% v 48%;P<0.001),且首次FDA批准时间更快(中位5.7 v 7.1 v 8.9年;P=0.02)。
- 超罕见、罕见和常见孤儿药适应症较非孤儿药适应症提供显著更大的无进展生存获益(风险比0.53 v 0.51 v 0.49 v 0.64;P<0.001),但总生存获益无显著差异(0.50 v 0.73 v 0.71 v 0.74;P=0.06)。
- 在单臂试验中,超罕见孤儿药适应症的肿瘤缓解率高于罕见、常见孤儿药适应症和非孤儿药适应症(客观缓解率57% v 48% v 55% v 33%;P<0.001)。
- 超罕见孤儿药适应症较罕见、常见孤儿药适应症和非孤儿药适应症的疾病发病率/患病率、五年生存率和可用治疗数量更低,而每患者伤残调整生命年更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the US Food and Drug Administration (FDA) approval, trials, unmet needs, benefit, and pricing of ultra-rare (<6600 affected US citizens), rare (6600-200 000 citizens), and common (>200 000 citizens) orphan cancer drug indications and non-orphan cancer drug indications. DESIGN: Cross sectional analysis. SETTING: Data from Drugs@FDA, FDA labels, Global Burden of Disease study, and Medicare and Medicaid. POPULATION: 170 FDA approved drugs across 455 cancer indications between 2000 and 2022. MAIN OUTCOME MEASURES: Comparison of non-orphan and ultra-rare, rare, and common orphan indications regarding regulatory approval, trials, epidemiology, and price. Hazard ratios for overall survival and progression-free survival were meta-analyzed. RESULTS: 161 non-orphan and 294 orphan cancer drug indications were identified, of which 25 were approved for ultra-rare diseases, 205 for rare diseases, and 64 for common diseases. Drugs for ultra-rare orphan indications were more frequently first in class (76% v 48% v 38% v 42%; P<0.001), monotherapies (88% v 69% v 72% v 55%; P=0.001), for hematologic cancers (76% v 66% v 0% v 0%; P<0.001), and supported by smaller trials (median 85 v 199 v 286 v 521 patients; P<0.001), of single arm (84% v 44% v 28% v 21%; P<0.001) phase 1/2 design (88% v 45% v 45% v 27%; P<0.001) compared with rare and common orphan indications and non-orphan indications. Drugs for common orphan indications were more often biomarker directed (69% v 26% v 12%; P<0.001), first line (77% v 39% v 20%; P<0.001), small molecules (80% v 62% v 48%; P<0.001) benefiting from quicker time to first FDA approval (median 5.7 v 7.1 v 8.9 years; P=0.02) than those for rare and ultra-rare orphan indications. Drugs for ultra-rare, rare, and common orphan indications offered a significantly greater progression-free survival benefit (hazard ratio 0.53 v 0.51 v 0.49 v 0.64; P<0.001), but not overall survival benefit (0.50 v 0.73 v 0.71 v 0.74; P=0.06), than non-orphans. In single arm trials, tumor response rates were greater for drugs for ultra-rare orphan indications than for rare or common orphan indications and non-orphan indications (objective response rate 57% v 48% v 55% v 33%; P<0.001). Disease incidence/prevalence, five year survival, and the number of available treatments were lower, whereas disability adjusted life years per patient were higher, for ultra-rare orphan indications compared with rare or common indications and non-orphan indications. For 147 on-patent drugs with available data in 2023, monthly prices were higher for ultra-rare orphan indications than for rare or common orphan indications and non-orphan indications ($70 128 (£55 971; €63 370) v $33 313 v $16 484 v $14 508; P<0.001). For 48 on-patent drugs with available longitudinal data from 2005 to 2023, prices increased by 94% for drugs for orphan indications and 50% for drugs for non-orphan indications on average. CONCLUSIONS: The Orphan Drug Act of 1983 incentivizes development of drugs not only for rare diseases but also for ultra-rare diseases and subsets of common diseases. These orphan indications fill significant unmet needs, yet their approval is based on small, non-robust trials that could overestimate efficacy outcomes. A distinct ultra-orphan designation with greater financial incentives could encourage and expedite drug development for ultra-rare diseases.
引用
- Michaeli T, Jürges H, Michaeli DT, et al. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ. 2023. PMID: 37160306. doi:10.1136/bmj-2022-073242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。